Pharmacological and functional magnetic resonance imaging techniques in CNS drug discovery

Expert Opinion on Drug Discovery

Volumn 1, Issue 3, 2006, Pages 211-224

  Fox, Gerard B ^a   McGaraughty, Steve ^a   Luo, Yanping ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

anaesthetised; functional magnetic resonance imaging; pharmacological MRI

Indexed keywords

EID: 38349140429     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.3.211     Document Type: Review

References (82)

1. ADAMS CP, BRANTNER VV: Estimating the cost of new drug development: is it really $802 million? Health Aff. (2003) 22:151-185.
2. DIMASI JA, HANSEN RW, GRABOWSKI HG: The price of innovation: new estimates of drug development costs. J. Health Econ. (2003) 22:151-185.
3. ALAVIJEH MS, CHISHTY M, QAISER MZ, PALMER AM: Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx (2005) 2:554-571.
4. FITZGERALD GA: Anticipating change in drug development: the emerging era of translational medicine and therapeutics. Nat. Rev. Drug Discov. (2005) 4:815-818.
5. BUTCHER EC: Can cell systems biology rescue drug discovery? Nat. Rev. Drug Discov. (2005) 4:461-467.
6. VAN DER GREEF J, MCBURNEY RN: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov. (2005) 4:961-967.
7. SHAH YB, MARSDEN CA: The application of functional magnetic resonance imaging to neuropharmacology. Curr. Opin. Pharmacol. (2004) 4:517-521.
8. LESLIE RA, JAMES MF: Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol. Sci. (2000) 21:314-318.
9. CHEN YC, GALPERN WR, BROWNELL AL et al.: Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. (1997) 38:389-398.
10. REESE T, BJELKE B, PORSZASZ R et al.: Regional brain activation by bicuculline visualized by functional magnetic resonance imaging. Time-resolved assessment of bicuculline-induced changes in local cerebral blood volume using an intravascular contrast agent. NMR Biomed. (2000) 13:43-49.
11. SCHWARZ A, GOZZI A, REESE T et al.: Selective dopamine D3 receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain. Synapse. (2004) 54:1-10.
12. SHAH YB, PRIOR MJ, DIXON AL, MORRIS PG, MARSDEN CA: Detection of cannabinoid agonist evoked increase in BOLD contrast in rats using functional magnetic resonance imaging. Neuropharmacology (2004) 46:379-87.
13. JONES N, ONEILL MJ, TRICKLEBANK M, LIBRI V, WILLIAMS SC: Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging. Psychopharmacology (Berl). (2005) 180:743-751.
14. GOZZI A, SCHWARZ AJ, REESE T et al.: Functional magnetic resonance mapping of intracerebroventricular infusion of a neuroactive peptide in the anaesthetised rat. J. Neurosci. Methods (2005) 142:115-124.
15. GOZZI A, SCHWARZ A, REESE T, BERTANI S, CRESTAN V, BIFONE A: Region-specifice effects of nicotine on brain activity: a pharmacological MRI study in the drug-naive rat. Neuropsychopharmacology. (In Press).
16. SKOUBIS PD, HRADIL V, CHIN CL, LUO Y, FOX GB, MCGARAUGHTY S: Mapping brain activity following administration of a nicotinic acetylcholine receptor agonist, ABT-594, using functional magnetic resonance imaging in awake rats. Neuroscience (2006) 137:583-591.
17. CHEN YI, CHOI JK, JENKINS BG: Mapping interactions betweendopamine and adenosine A2a receptors using pharmacologic MRI. Synapse (2005) 55:80-88.
18. DIXON AL, PRIOR M, MORRIS PM, SHAH YB, JOSEPH MH, YOUNG AM: Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI. Neuropharmacology (2005) 48:236-45.
19. HEWITT KN, SHAH YB, PRIOR MJ et al.: Behavioural and pharmacological magnetic resonance imaging assessment of the effects of methylphenidate in a potential new rat model of attention deficit hyperactivity disorder. Psychopharmacology (Berl) (2005) 180:716-723.
20. NGUYEN TV, BROWNELL AL, IRIS CHEN YC et al.: Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse (2000) 36:57-65.
21. RISTERUCCI C, JEANNEAU K, SCHOPPENTHAU S et al.: Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia. Psychopharmacology (Berl) (2005) 180:724-734.
22. CHEN YC, MANDEVILLE JB, NGUYEN TV, TALELE A, CAVAGNA F, JENKINS BG: Improved mapping of pharmacologically induced neuronal activation using the IRON technique with superparamagnetic blood pool agents. J. Magn. Reson. Imaging (2001) 14:517-524.
23. LAHTI KM, FERRIS CF, LI F, SOTAK CH, KING JA: Imaging brain activity in conscious animals using functional MRI. J. Neurosci. Methods (1998) 82:75-83.
24. ROBERTS TPL, VAN BRUGGEN N: Principles of MRI contrast. In: Biomedical Imaging in Experimental Neuroscience. Van Bruggen N, Roberts T (Eds), CRC Press, Boca Raton, USA (2003):1-20.
25. OGAWA S, LEE TM, KAY AR, TANK DW: Brain magnetic resonance imaging with contrast dependent on blood oxygenation. (1990) 87:9868-9872.
26. BANDETTINI PA, WONG EC, HINKS RS, TIKOFSKY RS, HYDE JS: Time course EPI of human brain function during task activation. Magn. Reson. Med. (1992) 25:390-397.
27. BLAMIRE AM, OGAWA S, UGURBIL K et al.: Dynamic mapping of the human visual cortex by high-speed magnetic resonance imaging. Proc. Natl. Acad. Sci. USA(1992) 89:11069-11073.
28. OGAWA S, TANK DW, MENON R et al.: Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc. Natl. Acad. Sci. USA (1992) 89:5951-5955.
29. DUNCAN GE, STUMPF WE: Brain activity patterns: assessment by high resolution autoradiographic imaging of radiolabeled 2-deoxyglucose and glucose uptake. Prog. Neurobiol. (1991) 37:365-382.
30. STEWARD CA, MARSDEN CA, PRIOR MJ, MORRIS PG, SHAH YB: Methodological considerations in rat brain BOLD contrast pharmacological MRI. Psychopharmacology (2005) 180:687-704.
31. ROSEN BR, BELLIVEAU JW, VEVEA JM, BRADY TJ: Perfusion imaging with NMR contrast agents. Magn. Reson. Med. (1990) 14:249-265.
32. VAN BRUGGEN N, BUSCH E, PALMER JT, WILLIAMS SP, DE CRESPIGNY AJ: High-resolution functional magnetic resonance imaging of the rat brain: mapping changes in cerebral blood volume using iron oxide contrast media. J. Cereb. Blood Flow Metab. (1998) 18:1178-1183.
33. MANDEVILLE JB, MAROTA JJ, KOSOFSKY BE et al.: Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn. Reson. Med. (1998) 39:615-624.
34. MANDEVILLE JB, JENKINS BG, KOSOFSKY BE, MOSKOWITZ MA, ROSEN BR, MAROTA JJ: Regional sensitivity and coupling of BOLD and CBV changes during stimulation of rat brain. Magn. Reson. Med. (2001) 45:443-447.
35. MANDEVILLE JB, MAROTA JJ: Vascular filters of functional MRI: spatial localization using BOLD and CBV contrast. Magn. Reson. Med. (1999) 42:591-598.
36. LYTHGOE MF, THOMAS DL, CALAMANTE F: MRI measurement of cerebral perfusion and application to experimental neuroscience. In: Biomedical Imaging in Experimental Neuroscience. van Bruggen N and Roberts T (Ed), CRC Press, Boca Raton, USA (2003):21-54.
37. ROY CS, SHERRINGTON CS: On the regulation of the blood supply of the brain. J. Physiol. Lond. (1890) 11:85-108.
38. ARTHURS OJ, STEPHENSON CM, RICE K et al.: Dopaminergic effects on electrophysiological and functional MRI measures of human cortical stimulus-response power laws. Neuroimage (2004) 21:540-546.
39. HUETTEL SA, OBEMBE OO, SONG AW, WOLDORFF MG: The BOLD fMRI refractory effect is specific to stimulus attributes: evidence from a visual motion paradigm. Neuroimage (2004) 23:402-408.
40. LOGOTHETIS NK, PAULS J, AUGATH M, TRINATH T, OELTERMANN A: Neurophysiological investigation of the basis of the fMRI signal. Nature (2001) 412:50-157.
41. DI SALLE F, ESPOSITO F, ELEFANTE A et al.: High field functional MRI. Eur. J. Radiol. (2003) 48:138-145.
42. DUONG TQ, YACOUB E, ADRIANY G, HU X, UGURBIL K, KIM SG: Microvascular BOLD contribution at 4 and 7 T in the human brain: gradient-echo and spin-echo fMRI with suppression of blood effects. Magn. Reson. Med. (2003) 49:1019-1027.
43. DEVLIN JT, RUSSELL RP, DAVIS MH et al.: Susceptibility-induced loss of signal: comparing PET and fMRI on a semantic task. Neuroimage (2000) 11:589-600.
44. LEE SP, SILVA AC, UGURBIL K, KIM SG: Diffusion-weighted spin-echo fMRI at 9.4 T: microvascular/tissue contribution to BOLD signal changes. Magn. Reson. Med. (1999) 42:919-928.
45. LOGOTHETIS NK: The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2002) 357:1003-1037.
46. TURNER R, HOWSEMAN A, REES GE, JOSEPHS O, FRISTON K: Functional magnetic resonance imaging of the human brain: data acquisition and analysis. Exp. Brain Res. (1998) 123:5-12.
47. FRISTON KJ, HOLMES AP, POLINE JB et al.: Analysis of fMRI time-series revisited. Neuroimage (1995) 2:45-53.
48. MCKEOWN MJ, SEJNOWSKI TJ: Independent component analysis of fMRI data: examining the assumptions. Hum. Brain Mapp. (1998) 6:368-372.
49. SOMORJAI RL, NIKULIN AE, PIZZI N et al.: Computerized consensus diagnosis: a classification strategy for the robust analysis of MR spectra. I. Application to 1H spectra of thyroid neoplasms. Magn. Reson. Med. (1995) 33:257-263.
50. COX RW: AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput. Biomed. Res. (1996) 29:162-173.
51. VAN BRUGGEN N, ROBERTS TP: The future for biomedical imaging. In: Biomedical Imaging in Experimental Neuroscience. (Ed), CRC Press, Boca Raton, USA (2003):323-337.
52. SHAH YB, HAYNES L, PRIOR MJ, MARSDEN CA, MORRIS PG, CHAPMAN V: Functional magnetic resonance imaging studies of opioid receptor-mediated modulation of noxious-evoked BOLD contrast in rats. Psychopharmacology (Berl) (2005) 80:761-773.
53. KALISCH R, SALOME N, PLATZER S et al.: High trait anxiety and hyporeactivity to stress of the dorsomedial prefrontal cortex: a combined phMRI and Fos study in rats. Neuroimage (2004) 23:382-391.
54. SMALL SA, WU EX, BARTSCH D et al.: Imaging physiologic dysfunction of individual hippocampal subregions in humans and genetically modified mice. Neuron (2000) 28:653-664.
55. CHEN Z, SILVA AC, YANG J, SHEN J: Elevated endogenous GABA level correlates with decreased fMRI signals in the rat brain during acute inhibition of GABA transaminase. J. Neurosci. Res. (2005) 79:383-391.
56. WEBER R, RAMOS-CABRER P, WIEDERMANN D, VAN CAMP N, HOEHN M: A fully noninvasive and robust experimental protocol for longitudinal fMRI studies in the rat. Neuroimage (2006) 29:1303-1310.
57. KEOGH BP, CORDES D, STANBERRY L et al.: BOLD-fMRI of PTZ-induced seizures in rats. Epilepsy Res. (2005) 66:75-90.
58. PELLED G, BERGMAN H, GOELMAN G: Bilateral overactivation of the sensorimotor cortex in the unilateral rodent model of Parkinsons disease - a functional magnetic resonance imaging study. Eur. J. Neurosci. (2002) 15:389-394.
59. BARON R, BARON Y, DISBROW E, ROBERTS TP: Brain processing of capsaicin-induced secondary hyperalgesia: a functional MRI study. Neurology (1999) 53:548-557.
60. MALISZA KL, DOCHERTY JC: Capsaicin as a source for painful stimulation in functional MRI. J. Magn. Reson. Imaging (2001) 14:341-347.
61. KUMARI V, GRAY JA, FFYTCHE DH et al.: Cognitive effects of nicotine in humans: an fMRI study. Neuroimage (2003) 19:1002-1013.
62. ROSE SE, JANKE AL, STRUDWICK MW et al.: Assessment of dynamic susceptibility contrast cerebral blood flow response to amphetamine challenge: a human pharmacological magnetic resonance imaging study at 1.5 and 4 T. Magn. Reson. Med. (2006) 55:9-15.
63. CHEN YC, CHOI JK, ANDERSEN SL, ROSEN BR, JENKINS BG: Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) (2005) 180:705-715.
64. HONEY GD, SUCKLING J, ZELAYA F et al.: Dopaminergic drug effects on physiological connectivity in a human cortico-striato-thalamic system. Brain. (2003) 126:1767-1781.
65. BALIKI M, KATZ J, CHIALVO DR, APKARIAN AV: Single subject pharmacological-MRI (phMRI) study: modulation of brain activity of psoriatic arthritis pain by cyclooxygenase-2 inhibitor. Mol. Pain (2005) 1:32.
66. GOEKOOP R, SCHELTENS P, BARKHOF F, ROMBOUTS SA: Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation - a pharmacological fMRI study. Brain. (2006) 129:141-157.
67. PAULSEN JS, ZIMBELMAN JL, HINTON SC et al.: fMRI biomarker of early neuronal dysfunction in presymptomatic Huntingtons Disease. Am. J. Neuroradiol. (2004) 25:1715-1721.
68. SHELINE YI, BARCH DM, DONNELLY JM, OLLINGER JM, SNYDER AZ, MINTUN MA: Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol. Psychiatry. (2001) 50:651-658.
69. CASEY KL: Concepts of pain imaging: the contribution of functional imaging of the human brain. In: Progress in Brain Res. Sandhuhler J, Bromm B, Ebhart GF (Eds), Elsevier Science. USA (2000) 129:277-287.
70. KING JA, GARELICK TS, BREVARD ME et al.: Procedure for minimizing stress for fMRI studies in conscious rats. J. Neurosci. Methods (2005) 148:154-160.
71. UEKI M, MIES G, HOSSMANN KA: Effect of α-chloralose, halothane, pentobarbital and nitrous oxide anesthesia on metabolic coupling in somatosensory cortex of rat. Acta. Anaesthesiol. Scand. (1992) 36:318-322.
72. SICARD K, SHEN Q, BREVARD ME et al.: Regional cerebral blood flow and BOLD responses in conscious and anesthetized rats under basal and hypercapnic conditions: implications for functional MRI studies. J. Cereb. Blood Flow Metab. (2003) 23:472-481.
73. TRACEY I: Prospects for human pharmacological functional magnetic resonance imaging (phMRI). J. Clin. Pharmacol. (2001) Suppl.: 21S-28S.
74. HONEY G, BULLMORE E: Human pharmacological MRI. Trends Pharmacol. Sci. (2004) 25:366-374.
75. JASANOFF A: Functional MRI using molecular imaging agents. Trends Neurosci. (2005) 28:120-126.
76. HEEGER DJ, RESS D: What does fMRI tell us about neuronal activity? Nat. Rev. Neurosci. (2002) 3:142-151.
77. FEBO M, SEGARRA AC, NAIR G, SCHMIDT K, DUONG TQ, FERRIS CF: The neural consequences of repeated cocaine exposure revealed by functional MRI in awake rats. Neuropsychopharmacology (2005) 30:936-493
78. http://www.FDA.gov Homepage for the food and drug administration.
79. http://www.ge.com The company website for General Electric.
80. http://afni.nimh.nih.gov/afni The AFNI/NIfTI server. Provides free software for the analysis and display of fMRI data.
81. http://www.fil.ion.ucl.ac.uk/spm SPM is a software package for MATLAB for the analysis of brain imaging data sequences.
82. http://www.fmrib.ox.ac.uk/fsl FSL is a comprehensive library of image analysis and statistical tools for fMRI, MRI and DTI brain imaging data written mainly by members of the Analysis Group, FMRIB, Oxford, UK.